Floatz logo

Futibatinib

Advanced or Metastatic Solid Tumor

Taiho Pharmaceutical Co., Ltd.Small moleculePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Advanced or Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Bayer
Phase 1CC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Bayer
Phase 1CC
Rogaratinib
Bayer
Phase 1CC
Inno-206
Bayer
Phase 1CC
(+)-VINCRISTINE
Taiho Pharmaceutical Co., Ltd.
Phase 1CC

View all 27 →

Same molecule, other indications

Futibatinib is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
gastroesophageal cancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →